Skip to Main Content

Paper Details

CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
Blood Adv
10
2023
-redirected T cells, AML, AML, T-ALL, and MM cell lines, CART-38, CART-38 cells, CARs, CD38, CD38-expressing malignancies, Chimeric antigen receptor, MM, T cells, T-ALL, T-cell acute lymphoblastic leukemia, activated T cells, chimeric antigen receptor, chimeric antigen receptor T cells, hematologic malignancies, hematopoietic progenitors, human, human CD38, human CD38-redirected T cells, mice, multiple myeloma, myeloid leukemia, patient, primary samples
Author NameAffiliation
Carl H JuneCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine
Sarah K TasianCenter for Childhood Cancer Research, The Children's Hospital of Philadelphia
Sarah K TasianUniversity of Pennsylvania Perelman School of Medicine
Richard AplencCenter for Childhood Cancer Research, The Children's Hospital of Philadelphia
Richard AplencUniversity of Pennsylvania Perelman School of Medicine
Richard AplencCenter for Childhood Cancer Research, The Children's Hospital of Philadelphia
Richard AplencUniversity of Pennsylvania Perelman School of Medicine
  • 1 - 7

Datasets

Release 1.2